Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jun 18, 2021 10:53am
161 Views
Post# 33411058

RE:Chunk

RE:Chunk It looks like someone wanted to get a position before Monday's webinar. Given the low liquidity seen recently, I would have thought traders would not have waited until the last minute to get positioned. It will be interesting to see how the day plays out - will there be more trying to get in ahead of Monday or is what we have seen already all that is going to be seen?

It seems like a pretty low risk trade since the chances of good news coming out Monday on the all-important cancer drug is high and the risk of bad news is pretty low. You don't put on shows like this to announce bad news (although you may sneak some into your overall bullish presentation). 

If you are looking to trade it, it is probably best to nail down your position today since there could easily be a press release Monday morning with cancer info in it that will have the market moving prior to the 11AM webinar start.

We really did not get anything new released this week to draw investor attention to the webinar, which I hope will not prove to be a missed opportunity. Hopefully, LSA has got some new potential investors lined up to participate because nothing has happened this week to bring in any new folks. The launch of the new website this weeek is a good indication they think more will be looking to examine it next week, so that may be a good sign.

Also, my best guess is that tomorrow's webinar is just the first in a series of things LSA is orchestrating to draw attention to TH's shares. Perhaps we will soonhave a KOL webinar with Dr. Grinspoon following the release of the NASH phase III protocol. LSA might issue a big report on TH. Maybe there will be fireside chats or an R&D Day in the company's future. These are the type of things LSA has normally done for its clients. 

Bucknelly21 wrote: Looks like someone bought a decent chunk right off the bat this morning 


<< Previous
Bullboard Posts
Next >>